Kolloquium „Statistische Methoden in der empirischen Forschung“

Wann: 05. Dezember 2023, 17:00 – 18:30 Uhr

Wo: Dieser Vortrag findet ausschließlich **ONLINE** statt.

Online-Übertragung: der Link wird auf der Website zur Verfügung gestellt

Heiner Bucher (Universität Basel)

Why do we need Real World Evidence Data?

Real World Evidence (RWE) deals with the assessment of potential benefits or risks of medical products or interventions that is generated by different study designs or analyses, including but not limited to randomized trials. These designs include pragmatic trials, and observational studies (prospective and/or retrospective).
RWE has the potential for complementing the knowledge gained from clinical trials that are for example confined to surrogate endpoints by providing best estimates for patient relevant endpoints of different treatments. RWE may generate evidence of higher external validity by inclusion of patients not typically enrolled in trials that better reflect situations of comorbidities and competing risks and who are cared in different health care setting. Pragmatic trials and nested trials may be based on large observational data or registries and may allow for more efficient and cheaper conduct of clinical trials. RWE is becoming more and more important in HTA to document the additional benefit from innovative drugs that receive approval from single arm studies. Finally, RWE may generate important data for health care systems research, quality improvement and surveillance studies.
The potential of RWE data is illustrated by selected examples of own research in HIV and antibiotic stewardship in Switzerland by use of target trial simulation, pragmatic and platform trial design. The examples illustrate how gaps in digitalization of health care systems could be closed and how to improve patient relevant outcomes research.